X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (64) 64
index medicus (62) 62
male (50) 50
female (38) 38
middle aged (31) 31
oncology (31) 31
adult (27) 27
aged (21) 21
animals (21) 21
lung neoplasms - drug therapy (18) 18
chemotherapy (17) 17
lung cancer (16) 16
treatment outcome (16) 16
cancer (13) 13
carcinoma, non-small-cell lung - drug therapy (13) 13
disease-free survival (13) 13
medicine (13) 13
mice (12) 12
research (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
genetic aspects (11) 11
lung neoplasms - pathology (11) 11
lung cancer, non-small cell (10) 10
medical research (10) 10
gene expression (9) 9
genes (9) 9
magnetic resonance imaging (9) 9
prognosis (9) 9
research article (9) 9
aged, 80 and over (8) 8
analysis (8) 8
carcinoma, non-small-cell lung - genetics (8) 8
carcinoma, non-small-cell lung - pathology (8) 8
care and treatment (8) 8
kaplan-meier estimate (8) 8
lung neoplasms - genetics (8) 8
multidisciplinary sciences (8) 8
mutation (8) 8
rats (8) 8
science (8) 8
clinical trials (7) 7
endocrinology & metabolism (7) 7
expression (7) 7
gefitinib (7) 7
genomes (7) 7
oxidative stress (7) 7
studies (7) 7
tumors (7) 7
antineoplastic agents - therapeutic use (6) 6
biochemistry & molecular biology (6) 6
cell biology (6) 6
diagnosis (6) 6
disease progression (6) 6
erlotinib (6) 6
lung neoplasms - mortality (6) 6
neoplasm staging (6) 6
patients (6) 6
phase-ii trial (6) 6
survival analysis (6) 6
therapy (6) 6
antineoplastic agents - adverse effects (5) 5
biology (5) 5
carboplatin - administration & dosage (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
case-control studies (5) 5
development and progression (5) 5
double-blind method (5) 5
drug therapy (5) 5
evolution (5) 5
genomics (5) 5
insulin resistance (5) 5
medicine, general & internal (5) 5
metastasis (5) 5
oncology, experimental (5) 5
rats, sprague-dawley (5) 5
respiratory system (5) 5
time factors (5) 5
transcription (5) 5
3t3-l1 cells (4) 4
abridged index medicus (4) 4
adipogenesis - genetics (4) 4
aids (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
article subject (4) 4
cancer therapies (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - metabolism (4) 4
cell line, tumor (4) 4
chinese (4) 4
combination (4) 4
economic conditions (4) 4
engineering, biomedical (4) 4
free radicals (4) 4
gene (4) 4
gene-expression (4) 4
genetic association studies (4) 4
genetic predisposition to disease (4) 4
glucose (4) 4
hiv (4) 4
hospitals (4) 4
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (9) 9
UTL at Downsview - May be requested (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Stacks (1) 1
Trinity College (John W Graham) - Reference (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lung Cancer, ISSN 0169-5002, 06/2018, Volume 120, pp. 27 - 33
There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of... 
Nintedanib | Squamous | Non-small cell lung cancer | Medicine, Experimental | Medical research | Lung cancer, Small cell | Care and treatment | Lung cancer, Non-small cell
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 04/2016, Volume 5, Issue 2, pp. 208 - 211
Journal Article
by Jamal-Hanjani, Mariam and Wilson, Gareth A and McGranahan, Nicholas and Birkbak, Nicolai J and Watkins, Thomas B.K and Veeriah, Selvaraju and Shafi, Seema and Johnson, Diana H and Mitter, Richard and Rosenthal, Rachel and Salm, Max and Horswell, Stuart and Escudero, Mickael and Matthews, Nik and Rowan, Andrew and Chambers, Tim and Moore, David A and Turajlic, Samra and Xu, Hang and Lee, Siow-Ming and Forster, Martin D and Ahmad, Tanya and Hiley, Crispin T and Abbosh, Christopher and Falzon, Mary and Borg, Elaine and Marafioti, Teresa and Lawrence, David and Hayward, Martin and Kolvekar, Shyam and Panagiotopoulos, Nikolaos and Janes, Sam M and Thakrar, Ricky and Ahmed, Asia and Blackhall, Fiona and Summers, Yvonne and Shah, Rajesh and Joseph, Leena and Quinn, Anne M and Crosbie, Phil A and Naidu, Babu and Middleton, Gary and Langman, Gerald and Trotter, Simon and Nicolson, Marianne and Remmen, Hardy and Kerr, Keith and Chetty, Mahendran and Gomersall, Lesley and Fennell, Dean A and Nakas, Apostolos and Rathinam, Sridhar and Anand, Girija and Khan, Sajid and Russell, Peter and Ezhil, Veni and Ismail, Babikir and Irvin-Sellers, Melanie and Prakash, Vineet and Lester, Jason F and Kornaszewska, Malgorzata and Attanoos, Richard and Adams, Haydn and Davies, Helen and Dentro, Stefan and Taniere, Philippe and O’Sullivan, Brendan and Lowe, Helen L and Hartley, John A and Iles, Natasha and Bell, Harriet and Ngai, Yenting and Shaw, Jacqui A and Herrero, Javier and Szallasi, Zoltan and Schwarz, Roland F and Stewart, Aengus and Quezada, Sergio A and Le Quesne, John and Van Loo, Peter and Dive, Caroline and Hackshaw, Allan and Swanton, Charles and TRACERx Consortium
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2109 - 2121
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Science, ISSN 0036-8075, 10/2014, Volume 346, Issue 6206, pp. 251 - 256
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1692 - 1698
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2013, Volume 105, Issue 9, pp. 595 - 605
Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for regulating tumorigenesis and cell survival and may be important in the... 
TYROSINE KINASE INHIBITORS | PHASE-III TRIAL | 1ST-LINE TREATMENT | GEFITINIB | ONCOLOGY | CLINICAL-TRIALS | 2ND-LINE TREATMENT | OPEN-LABEL | NEVER-SMOKERS | ERLOTINIB | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Cisplatin - administration & dosage | Female | Quinazolines - administration & dosage | Deoxycytidine - administration & dosage | Carcinoma, Non-Small-Cell Lung - metabolism | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Deoxycytidine - analogs & derivatives | Guanine - administration & dosage | Protein-Tyrosine Kinases - antagonists & inhibitors | Usage | Gene mutations | Analysis | Patient outcomes | Physiological aspects | Development and progression | Genetic aspects | Research | Lung cancer, Non-small cell | Meta-analysis
Journal Article
Respirology, ISSN 1323-7799, 04/2010, Volume 15, Issue 3, pp. 387 - 392
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 11, pp. 1161 - 1170
Journal Article
PLoS Biology, ISSN 1544-9173, 2014, Volume 12, Issue 7, pp. 1 - 7
Journal Article